肝障害および非アルコール性脂肪性肝炎時の従来型 合成、分子標的型合成、生物学的抗リウマチ薬による 関節リウマチ治療
Rheumatol Int. 2022 doi: 10.1007/s00296-022-05143-y
An increased incidence of liver diseases emphasizes greater caution in prescribing antirheumatic drugs, owing to their hepatotoxicity. However, drug-induced liver injury (DILI) in RA patients represents an aetiological and therapeutic challenge, due to the intertwining of inflammatory and metabolic elements mediated by IL-6 and TNF-α.
In this narrative review, Zekić, et al. evaluate the complexity and prevention of DILI in RA and treatment options involving biological therapy and tsDMARDs.
